Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis

Table 3 Cox model analysis for 87 ESCC patients with locoregional recurrence before matching

Variable	n	Univariate			Multivariate
Variable	n	HR	95%CI	P	HR	95%CI	P
Age (years)
< 65/≥65	58/29	0.786	0.467–1.322	0.364
KPS
70–80/>80	32/55	0.752	0.467–1.212	0.243
Gender
Male/Female	65/22	1.008	0.607–1.673	0.976
Smoking
Yes/No	31/56	1.438	0.893–2.317	0.135
Alcohol consumption
Yes/No	15/72	1.229	0.668–2.261	0.507
Primary tumor location
Upper/Middle and lower thoracic	34/53	1.241	0.779–1.977	0.364
Clinical stage
I + II/III	26/61	1.083	0.645–1.820	0.763	1.027	0.599–1.761	0.923
Surgery in the initial treatment
Yes/No	11/76	1.161	0.608–2.216	0.652
Chemotherapy in the initial treatment
Yes/No	43/44	0.954	0.601–1.514	0.842
Recurrence-free interval (months)
≤12/> 12	38/49	0.884	0.558–1.402	0.601
Pattern of recurrence
LN/PF	14/73	0.385	0.195–0.762	0.006	0.461	0.221–0.964	0.040
Re-RT after recurrence
Yes/No	39/48	0.392	0.239–0.642	< 0.001	0.513	0.299–0.878	0.015
Chemotherapy after recurrence
Yes/No	26/61	0.799	0.478–1.335	0.391
Chemotherapy for both course treatment
Yes/No	13/74	0.540	0.274–1.063	0.074	0.520	0.257–1.051	0.069

Abbreviations: HR Hazard ratio, 95%CI 95% confidence interval, Re-RT Re-irradiation, LN Regional lymph node recurrence only, PF Primary failure with/without regional lymph node recurrence, KPS Karnofsky performance status

ISSN: 1748-717X